Contact_NN information_NN Registered_NNP office_NN and_CC corporate_JJ headquarters_NN address_NN AstraZeneca_NNP PLC_NNP 15_CD Stanhope_NNP Gate_NNP London_NNP W1K_NNP 1LN_NNP UK_NNP Tel_NNP :_: 44_CD 0_CD 20 7304 5000_CD Fax_NNP :_: 44_CD 0_CD 20 7304 5183_CD R&D_NNP headquarters_NN address_NN AstraZeneca_NNP AB_NNP R&D_NNP Headquarters_NNP SE-151_NNP 85_CD Sdertlje_NNP Sweden_NNP Tel_NNP :_: 46_CD 0_CD 8_CD 553_CD 260_CD 00_CD Fax_NN :_: 46_CD 0_CD 8_CD 553_CD 290_CD 00_CD Investor_NNP relations_NNS contacts_NNS UK_NNP and_CC Sweden_NNP :_: as_IN above_IN or_CC e-mail_VB IR@astrazeneca_NNP ._.
com_NN US_NNP :_: Investor_NNP Relations_NNP AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP 1800_CD Concord_NNP Pike_NNP PO_NNP Box_NNP 15438_CD Wilmington_NNP fide_NN 19850-5438_CD US_NNP Tel_NNP :_: 1_CD 302 886 3000_CD Fax_NNP :_: 1_CD 302 886 2972_CD Registrar_NNP and_CC transfer_VB office_NN Lloyds_NNP TSB_NNP Registrars_NNPS The_DT Causeway_NNP Worthing_NNP West_NNP Sussex_NNP BN99_NNP 6DA_NNP UK_NNP Tel_NNP in_IN the_DT UK_NNP :_: 0870 600 3956_CD Tel_NNP outside_IN the_DT UK_NNP :_: 44 121 415 7033_CD Swedish_JJ securities_NNS registration_NN center_NN VPC_NNP AB_NNP PO_NNP Box_NNP 7822_CD SE-103_NNP 97_CD Stockholm_NNP Sweden_NNP Tel_NNP :_: 46_CD 0_CD 8_CD 402_CD 9000_CD US_NNP depositary_JJ JPMorgan_NNP Chase_NNP Bank_NNP PO_NNP Box_NNP 43013_CD Providence_NNP RI_NNP 02940-3013_CD US_NNP Tel_NNP toll_NN free_JJ in_IN the_DT US_NNP :_: 888 697 8018_CD Tel_NNP :_: 1_CD 781 575 4328_CD astrazeneca_NN ._.
com_NN Annual_JJ Review_NNP 2004_CD thinking_VBG people_NNS thinking_VBG performance_NN Annual_JJ Review_NNP 2004_CD 01_CD astrazeneca_NN ._.
com_NN The_DT year_NN in_IN brief_JJ AstraZeneca_NNP is_VBZ one_CD of_IN the_DT worlds_NNS Group_NNP sales_NNS up_IN 9_CD %_NN at_IN constant_JJ exchange_NN rates_NNS to_TO $_$ 21.4_CD billion_CD strong_JJ leading_VBG pharmaceutical_JJ companies_NNS ._.
sales_NNS performance_NN from_IN key_JJ growth_NN products_NNS up_IN 30_CD %_NN to_TO $_$ 11.2_CD billion_CD We_PRP focus_VB our_PRP$ skills_NNS ,_, experience_NN Operating_NN profit_NN up_RB 15_CD %_NN at_IN constant_JJ exchange_NN rates_NNS to_TO $_$ 4.8_CD billion_CD EPS_NNP and_CC resources_NNS on_IN six_CD therapy_NN pre-exceptional_JJ items_NNS up_IN 18_CD %_NN areas_NNS :_: cancer_NN ,_, cardiovascular_JJ ,_, gastrointestinal_JJ ,_, infection_NN ,_, Dividend_NN increased_VBN by_IN 18_CD %_NN to_TO $_$ 0.94_CD for_IN the_DT full_JJ year_NN neuroscience_NN ,_, and_CC respiratory_JJ and_CC inflammation_NN important_JJ Nexium_NNP sales_NNS reached_VBD $_$ 3.9_CD billion_CD ,_, up_RB 15_CD %_NN areas_NNS of_IN healthcare_NN that_IN represent_VBP the_DT majority_NN of_IN the_DT worldwide_JJ Seroquel_NNP sales_NNS increased_VBN by_IN 33_CD %_NN to_TO just_RB over_IN $_$ 2_CD billion_CD burden_NN of_IN disease_NN ._.
We_PRP have_VBP a_DT broad_JJ range_NN of_IN products_NNS for_IN Symbicort_NNP sales_NNS totalled_VBD $_$ 797_CD million_CD ,_, up_RB 32_CD %_NN these_DT areas_NNS and_CC a_DT commitment_NN to_TO delivering_VBG a_DT flow_NN of_IN new_JJ Expanded_VBN use_NN of_IN Arimidex_NNP in_IN the_DT treatment_NN of_IN early_JJ stage_NN breast_NN cancer_NN medicines_NNS designed_VBN to_TO meet_VB the_DT underpinned_VBN 48_CD %_NN increase_NN in_IN sales_NNS to_TO $_$ 811_CD million_CD needs_NNS of_IN patients_NNS and_CC the_DT healthcare_NN professionals_NNS who_WP treat_VBP them_PRP ._.
Crestor_NNP sales_NNS totalled_VBD $_$ 908_CD million_CD despite_IN challenging_JJ environment_NN ._.
Sales_NNS impacted_VBN by_IN allegations_NNS regarding_VBG the_DT products_NNS safety_NN ._.
Clinical_JJ trials_NNS experience_NN and_CC post-marketing_JJ surveillance_NN continue_VBP to_TO support_VB our_PRP$ belief_NN that_IN the_DT safety_NN profile_NN is_VBZ in_IN line_NN with_IN other_JJ marketed_VBN statins_NNS FDA_NNP decision_NN not_RB to_TO approve_VB Exanta_NNP ._.
In_IN the_DT EU_NNP ,_, where_WRB Exanta_NNP already_RB marketed_VBD for_IN acute_JJ indications_NNS ,_, more_JJR data_NNS have_VBP been_VBN requested_VBN before_IN approval_NN of_IN use_NN in_IN chronic_JJ indication_NN can_MD be_VB considered_VBN Results_NNS of_IN ISEL_NNP clinical_JJ study_NN for_IN Iressa_NNP showed_VBD no_DT statistically_RB significant_JJ increase_NN in_IN survival_NN of_IN overall_JJ population_NN ._.
Data_NNP suggest_VBP survival_NN benefits_NNS in_IN patient_JJ populations_NNS of_IN East_JJ Asian_JJ origin_NN and_CC non-smokers_NNS R&D_NNP investment_NN totalled_VBD $_$ 3.8_CD billion_CD ._.
40_CD %_NN more_JJR projects_NNS in_IN clinical_JJ development_NN phases_NNS 1_CD and_CC 2_CD than_IN in_IN 2003_CD ._.
31_CD projects_NNS in_IN pre-clinical_JJ testing_NN 26_CD in_IN 2003_CD Important_JJ strategic_JJ alliance_NN with_IN Cambridge_NNP Antibody_NNP Technology_NNP to_TO discover_VB and_CC develop_VB human_JJ antibody_NN therapeutics_NNS in_IN inflammatory_JJ disorders_NNS Global_JJ clinical_JJ trials_NNS website_VBP on_IN track_NN for_IN launch_NN in_IN the_DT first_JJ quarter_NN of_IN 2005_CD ._.
This_DT will_MD provide_VB a_DT detailed_JJ ,_, publicly_RB available_JJ ,_, scientific_JJ ,_, non-promotional_JJ summary_NN of_IN clinical_JJ trials_NNS conducted_VBN for_IN products_NNS approved_VBN since_IN AstraZeneca_NNP was_VBD formed_VBN in_IN 1999_CD Appointment_NN of_IN Executive_NNP Director_NNP for_IN Development_NNP as_IN part_NN of_IN accelerated_VBN significant_JJ program_NN of_IN change_NN to_TO optimise_VB the_DT contribution_NN of_IN our_PRP$ development_NN and_CC regulatory_JJ functions_NNS Contents_NNP Chairmans_NNPS statement_NN 02_CD Board_NNP of_IN Directors_NNS 18_CD Strategy_NNP 03_CD Summary_NNP Directors_NNS report_VBP 20_CD Chief_NNP Executives_NNS review_VBP 04_CD Remuneration_NNP policy_NN 22_CD Financial_NNP highlights_VBZ 05_CD Summary_NNP financial_JJ review_NN 24_CD AstraZeneca_NNP in_IN brief_JJ 05_CD Summary_NNP financial_JJ statements_NNS 27_CD Discovery_NNP 07_CD Auditors_NNS statement_NN 27_CD Development_NNP 08_CD Group_NNP profit_NN and_CC loss_NN account_NN 28_CD Development_NNP pipeline_NN 09_CD Group_NNP balance_NN sheet_NN 30_CD Sales_NNS and_CC marketing_NN 10_CD Statement_NN of_IN Group_NNP cash_NN flow_NN 31_CD Key_NNP products_NNS 10_CD Dividends_NNPS 32_CD Supply_NNP 12_CD Earnings_NNS per_IN share_NN 32_CD Product_NNP strategy_NN &_CC licensing_NN 13_CD Emoluments_NNS of_IN Directors_NNS 33_CD People_NNS 14_CD Group_NNP financial_JJ record_NN 34_CD Therapy_NNP area_NN review_NN 16_CD Shareholder_NN information_NN 35_CD
